Cargando…
Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
The question of whether UK oncologists follow current anthracycline dose modifications when treating patients with liver dysfunction was addressed through a questionnaire. Oncologists were asked the dose of doxorubicin or epirubicin they would prescribe for a woman with breast cancer and liver metas...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150122/ https://www.ncbi.nlm.nih.gov/pubmed/9569053 |
_version_ | 1782144578803990528 |
---|---|
author | Dobbs, N. A. Twelves, C. J. |
author_facet | Dobbs, N. A. Twelves, C. J. |
author_sort | Dobbs, N. A. |
collection | PubMed |
description | The question of whether UK oncologists follow current anthracycline dose modifications when treating patients with liver dysfunction was addressed through a questionnaire. Oncologists were asked the dose of doxorubicin or epirubicin they would prescribe for a woman with breast cancer and liver metastases who had one of four different patterns of abnormal liver chemistry. In each case, the median dose of anthracycline that would have been prescribed was close to that currently recommended. There was, however, wide variation in the dose that oncologists said they would prescribe, some avoiding an anthracycline altogether, whereas others would give full-dose treatment. Medical oncologists would prescribe a significantly lower dose of anthracycline than clinical oncologists for a patient with the most severely disturbed liver tests. Overall, medical oncologists were also significantly more likely to prescribe epirubicin. These results show the need for new, widely accepted anthracycline dose modifications for patients with liver dysfunction. |
format | Text |
id | pubmed-2150122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-21501222009-09-10 Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? Dobbs, N. A. Twelves, C. J. Br J Cancer Research Article The question of whether UK oncologists follow current anthracycline dose modifications when treating patients with liver dysfunction was addressed through a questionnaire. Oncologists were asked the dose of doxorubicin or epirubicin they would prescribe for a woman with breast cancer and liver metastases who had one of four different patterns of abnormal liver chemistry. In each case, the median dose of anthracycline that would have been prescribed was close to that currently recommended. There was, however, wide variation in the dose that oncologists said they would prescribe, some avoiding an anthracycline altogether, whereas others would give full-dose treatment. Medical oncologists would prescribe a significantly lower dose of anthracycline than clinical oncologists for a patient with the most severely disturbed liver tests. Overall, medical oncologists were also significantly more likely to prescribe epirubicin. These results show the need for new, widely accepted anthracycline dose modifications for patients with liver dysfunction. Nature Publishing Group 1998-04 /pmc/articles/PMC2150122/ /pubmed/9569053 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Dobbs, N. A. Twelves, C. J. Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title | Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title_full | Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title_fullStr | Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title_full_unstemmed | Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title_short | Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? |
title_sort | anthracycline doses in patients with liver dysfunction: do uk oncologists follow current recommendations? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150122/ https://www.ncbi.nlm.nih.gov/pubmed/9569053 |
work_keys_str_mv | AT dobbsna anthracyclinedosesinpatientswithliverdysfunctiondoukoncologistsfollowcurrentrecommendations AT twelvescj anthracyclinedosesinpatientswithliverdysfunctiondoukoncologistsfollowcurrentrecommendations |